

WHAT IS CLAIMED:

1. A method for enhancing or stimulating neurogenesis comprising administering to a human in need of such treatment a pharmaceutically effective amount of a compound which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine.
2. The method of claim 1 wherein the neurogenesis is in the limbic system or paralimbic system.
3. The method of claim 1 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
4. The method of claim 1 wherein the pharmaceutically effective amount comprises from about 0.25 mg to about 45 mg per day.
5. A method for treatment of symptoms of Cerebral Palsy comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.
6. The method of claim 5 wherein the symptoms include spasticity.
7. The method of claim 5 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
8. A method for treatment of claim 5 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
9. A method for treatment of claim 5 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.

10. A method for treatment of symptoms of Torticollis comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.
11. The method of claim 10 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
12. A method for treatment of claim 10 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
13. A method for treatment of claim 10 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.
14. A method for treatment of symptoms of Dystonia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.
15. The method of claim 14 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
16. A method for treatment of claim 14 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
17. A method for treatment of claim 14 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.
18. A method for treatment of symptoms of Dyskinesia, Tardive Dyskinesia, Lingual Dyskinesia and Facial Dyskinesia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.

19. The method of claim 18 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
20. A method for treatment of claim 18 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
21. A method for treatment of claim 18 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.
22. A method for treatment of symptoms of Institutionalization Syndrome and Concentration Camp Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.
23. The method of claim 22 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
24. A method for treatment of claim 22 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
25. A method for treatment of claim 22 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.
26. A method for treatment of symptoms of Dementia comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.
27. The method of claim 26 wherein the Dementia is Alzheimer's dementia or non-Alzheimer's dementia.

28. The method of claim 26 wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.
29. A method for treatment of claim 26 wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.
30. A method for treatment of claim 26 further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.